• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Clearmind Medicine Inc (NQ: CMND )

    1.840 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,229
    Open 1.840
    Bid (Size) 1.750 (6)
    Ask (Size) 1.890 (1)
    Prev. Close 1.840
    Today's Range 1.840 - 1.840
    52wk Range 0.9205 - 16.19
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
    Via Benzinga

    Performance

    YTD
    -33.81%
    -33.81%
    1 Month
    +10.84%
    +10.84%
    3 Month
    +53.33%
    +53.33%
    6 Month
    +24.32%
    +24.32%
    1 Year
    -86.06%
    -86.06%

    More News

    Read More
    Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024
    Via InvestorPlace
    Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
    Via Benzinga
    Exposures Fossil Fuels
    Why Is SciSparc (SPRC) Stock Up 25% Today?
    Via InvestorPlace
    Topics Intellectual Property
    Exposures Intellectual Property
    Dow Jumps 400 Points; US Retail Sales Flat For June
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
    From SciSparc Ltd
    Via GlobeNewswire
    Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Day Trading My Way From Red To Green
    Via Talk Markets
    Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    What's Going On With Clearmind Medicine Stock Tuesday?
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Why Clearmind Medicine Stock Is Moving Higher
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Clearmind Applies to Cease Being a Reporting Issuer in Canada
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
    Via Benzinga
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.